Revolutionizing Cell-Based Therapies: Pluri Inc.’s 3D Cell Expansion Technology Granted US Patent

Pluri Introduces Exclusive 3D Cell Expansion Technology

Pluri Inc., a biotechnology company, has recently been granted a new U.S. patent for its unique method of expanding immune cells using proprietary technology. The company’s 3D cell expansion technology is designed to replicate the natural environment in the human body where immune cells are found in lymph nodes. Through a closely monitored and fully automated bioreactor system, cells are provided with the necessary conditions for expansion, resulting in a scalable and high-quality process.

By ensuring that the immune cells retain their functionality, integrity, and therapeutic efficacy, this method offers a promising solution to the increasing demand for advanced cell-based therapies for immune disorders and neurodegenerative diseases. Pluri’s patented technology addresses the key challenges faced by existing allogeneic cell therapies, such as donor cell availability and scalability issues. This innovation has the potential to unlock new opportunities for therapeutic advancements and commercial success in the field.

According to Yaky Yanay, CEO and President of Pluri, the company’s dedication to technology and decades of experience have positioned them to develop cutting-edge medical treatments. The patented technology represents a significant advancement in immune cell expansion, meeting the rising global demand for advanced cell-based therapies. By leveraging their proprietary technology, Pluri aims to push the boundaries of allogeneic cell therapy and improve patient outcomes worldwide.

In addition to this milestone, earlier this year, Pluri Inc. introduced a new business division, PluriCDMO, which offers cell therapy manufacturing services as a Contract Development and Manufacturing Organization (CDMO). This expansion into manufacturing services further establishes Pluri’s commitment to advancing cell therapies and serving the needs of patients in need of innovative treatments. With these developments under its belt

Leave a Reply